Trial · NCT02888106
Outcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Patients With Negative HDV RNA by PCR | 72 weeks | FAS | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Patients With Negative HDV RNA by PCR | 24 and 48 weeks | FAS | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Patients With Normalized ALT | 24, 48 and 72 weeks | FAS | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Patients With Combined Response | 24, 48 and 72 weeks | FAS | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Patients With HВsAg Response | 24, 48 and 72 weeks | FAS | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Patients With HBsAg Negativation | 48 and 72 weeks | According to SAP Section 7.1.5 - Handling of missing data. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Patients With Negative HBV DNA by PCR | 24, 48 and 72 weeks | Percentage of participants | NUMBER | |
| SECONDARY | The Intensity of Liver Fibrosis Based on Results of Transient Elastometry of Liver at Weeks 48 and 72. | 48 and 72 weeks | FAS | kPa | MEAN |
| SECONDARY | Number of Participants With Change (Improvement / Worsening) in Fibrosis and Histological Activity Stage From Baseline to Post-treatment | 72 weeks | FAS | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change in Molecular Analyses of Relative HDV RNA Expression, Relative HBV Pregenomic Expression, Relative Total HBV RNA Expression (X Region), Relative HBV RNA Expression (S Region). | 48 and 72 weeks | FAS | Relative value | MEAN |
| SECONDARY | Change in Molecular Analyses of Total HBV DNA (X Region) Copies/Cell, HBV DNA (S Region) Copies/Cell, cccDNA Copies/Cell From Baseline to Post-treatment. | 48 and 72 weeks | FAS | Copies/cell | MEAN |
| SECONDARY | Change in Molecular Analysis of HDAg Positive Hepatocytes (%) From Baseline to Post-treatment | 48 and 72 weeks | FAS | Percentage | MEAN |
| SECONDARY | Change in the Gene Expression Analyses From Baseline to Post-treatment | Weeks 48 - 72 | FAS | Relative value | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02888106/outcomes